close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

35.00 -0.33 (-0.93%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
4 Analysts Have This to Say About Travere Therapeutics ↗
 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022 ↗
 
Via Benzinga
Where Travere Therapeutics Stands With Analysts ↗
 
Via Benzinga
News headline image
Recap: Travere Therapeutics Q3 Earnings ↗
Travere Therapeutics (NASDAQ:TVTX) reported its Q3 earnings results on Thursday, October 27, 2022 at 04:01 PM. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Analyst Cuts Price On Travere Therapeutics Citing Expected Delayed PDUFA ↗
 
Via Benzinga
News headline image
Expert Ratings for Travere Therapeutics ↗
Within the last quarter, Travere Therapeutics (NASDAQ:TVTX) has observed the following analyst ratings: 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  During Tuesday's trading, 160 companies set new 52-week lows. 
Via Benzinga
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics, the IgA Nephropathy Foundation, and NephCure Kidney International Partner to Launch RKD & Me, a Campaign to Raise Awareness of Rare Kidney Disease
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
FDA Requests For Additional Monitoring For Travere Therapeutics' Sparsentan In Rare Kidney Disease ↗
 
Via Benzinga
News headline image
Travere Therapeutics to Present at Upcoming Investor Conferences
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Earnings Perspective: Return On Capital Employed ↗
Benzinga Pro data, Travere Therapeutics (NASDAQ:TVTX) reported Q3 sales of $53.50 million. Earnings fell to a loss of $69.66 million, resulting in a 3.91% decrease from last quarter. 
Via Benzinga
News headline image
Provention Bio's Second Try, Apellis's Eye Disorder Drug Review, 3 Adcom Verdicts And More: November's Key PDUFA Catalysts Biotech Investors Must Know ↗
October proved to be a mixed month for the Food and Drug Administration’s regulatory decisions. Two new molecular entities, or NMEs, were approved during the month, bringing the tally for the... 
Via Benzinga
News headline image
Travere Therapeutics Reports Third Quarter 2022 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Return On Capital Employed Overview ↗
  
Via Benzinga
News headline image
Recap: Travere Therapeutics Q2 Earnings ↗
  Travere Therapeutics (NASDAQ:TVTX) reported its Q2 earnings results on Thursday, August 4, 2022. Here's what investors need to know about the announcement. 
Via Benzinga
News headline image
Earnings Scheduled For October 27, 2022 ↗
Companies Reporting Before The Bell • Janus Henderson Gr (NYSE:JHG) is expected to report quarterly earnings at $0.48 per share on revenue of $494.27 million. 
Via Benzinga
News headline image
Travere Therapeutics Announces Presentations and Posters at American Society of Nephrology Kidney Week 2022
Data support the Company’s lead investigational product candidate sparsentan 
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Earnings Outlook For Travere Therapeutics ↗
Travere Therapeutics (NASDAQ:TVTX) is set to give its latest quarterly earnings report on Thursday, 2022-10-27. Here's what investors need to know before the announcement. Analysts estimate that... 
Via Benzinga
News headline image
Travere Therapeutics to Report Third Quarter 2022 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Travere Therapeutics Provides Regulatory Update on its Sparsentan Program for IgA Nephropathy
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
121 Stocks That Hit Their 52-Week Low ↗
New Equities that Broke Through 52-Week Lows Friday Morning During Friday's morning session, 121 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
News headline image
Insider Buying 2022: 15 Stocks to Bet On Despite the Bear Market ↗
Following insider buying is a savvy way for retail investors to profit even when a bear market is raging on Wall Street. Here are 15 stocks. 
Via InvestorPlace
News headline image
Recap Of Monday's Biotech Catalysts - End Of the Day Summary ↗
 
Via Benzinga
News headline image
Travere, CSL's Sparsentan Application Is Under European Review For Rare Kidney Disorder ↗
 
Via Benzinga
News headline image
Biotech Daily: Amgen, Gilead Go Shopping, Nod For AstraZeneca's Lynparza In Early Stage Breast Cancer, Decision Day For Alzheimer's Associated Hallucinations Candidate ↗
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
News headline image
FDA Says Travere's Sparsentan Data Not Sufficient For Accelerated Approval In One Indication ↗
Travere Therapeutics Inc (NASDAQ: TVTX) completed its planned FDA Type A meeting for a potential submission for accelerated approval of sparsentan for focal segmental glomerulosclerosis (FSGS), a rare... 
Via Benzinga
News headline image
12 Health Care Stocks Moving In Wednesday's After-Market Session ↗
Gainers 
Via Benzinga
News headline image
4 Analysts Have This to Say About Travere Therapeutics ↗
Over the past 3 months, 4 analysts have published their opinion on Travere Therapeutics (NASDAQ:TVTX) stock. These analysts are typically employed by large Wall Street banks and tasked with... 
Via Benzinga
< Previous 1 2
...
7 8 9 10 11 12 13 14 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today